1
|
Gordon MF, Grachev ID, Mazeh I, Dolan Y, Reilmann R, Loupe PS, Fine S, Navon-Perry L, Gross N, Papapetropoulos S, Savola JM, Hayden MR. Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. Digit Biomark 2019; 3:103-115. [PMID: 32095771 DOI: 10.1159/000502136] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Accepted: 07/16/2019] [Indexed: 01/17/2023] Open
Abstract
Previous studies have demonstrated the feasibility and promise of wearable sensors as objective measures of motor impairment in Parkinson disease and essential tremor. However, there are few published studies that have examined such an application in Huntington disease (HD). This report provides an evaluation of the potential to objectively quantify chorea in HD patients using wearable sensor data. Data were derived from a substudy of the phase 2 Open-PRIDE-HD study, where 17 patients were screened and 15 patients enrolled in the substudy and ultimately 10 patients provided sufficient wearable sensor data. The substudy was designed to provide high-resolution data to inform design of predictive algorithms for chorea quantification. During the entire course of the 6-month study, in addition to chorea ratings from 18 in-clinic assessments, 890 home assessments, and 1,388 responses to daily reminders, 33,000 h of high-resolution accelerometer data were captured continuously from wearable smartwatches and smartphones. Despite its limited sample size, our study demonstrates that arm chorea can be characterized using accelerometer data during static assessments. Nonetheless, the small sample size limits the generalizability of the model. The sensor-based model can quantify the chorea level with high correlation to the chorea severity reported by both clinicians and patients. In addition, our analysis shows that the chorea digital signature varies between patients. This work suggests that digital wearable sensors have the potential to support clinical development of medications in patients with movement disorders, such as chorea. However, additional data would be needed from a larger number of HD patients with a full range of chorea severity (none to severe) with and without intervention to validate this potentially predictive technology.
Collapse
Affiliation(s)
- Mark Forrest Gordon
- Specialty Clinical Development, Teva Pharmaceutical Industries Ltd., Frazer, Pennsylvania, USA
| | - Igor D Grachev
- Guide Pharmaceutical Consulting, LLC, Millstone Township, New Jersey, USA
| | - Itzik Mazeh
- Advanced Analytics Department, Intel, Petah Tikva, Israel
| | - Yonatan Dolan
- Advanced Analytics Department, Intel, Petah Tikva, Israel
| | - Ralf Reilmann
- George Huntington Institute and Department of Radiology University of Münster, Münster, Germany.,Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
| | - Pippa S Loupe
- Specialty Research and Development, Teva Pharmaceutical Industries Ltd., New Orleans, Louisiana, USA
| | - Shai Fine
- Data Science Institute, Interdisciplinary Center, Herzliya, Israel
| | | | - Nicholas Gross
- Specialty Clinical Development, Teva Pharmaceutical Industries Ltd., Frazer, Pennsylvania, USA
| | | | | | - Michael R Hayden
- Global Research and Development, Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel.,Prilenia Therapeutics, Herzliya, Israel
| |
Collapse
|